LQ0 Stock Overview
Engages in the development of drug candidates with application in urological oncology, primarily prostate cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Dextech Medical AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.34 |
| 52 Week High | kr0.60 |
| 52 Week Low | kr0.31 |
| Beta | 1.47 |
| 1 Month Change | -18.27% |
| 3 Month Change | -40.56% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| LQ0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.1% | 0.6% | -0.4% |
| 1Y | n/a | -25.6% | 4.2% |
Return vs Industry: Insufficient data to determine how LQ0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how LQ0 performed against the German Market.
Price Volatility
| LQ0 volatility | |
|---|---|
| LQ0 Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: LQ0's share price has been volatile over the past 3 months.
Volatility Over Time: LQ0's weekly volatility has decreased from 12% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 1 | Anders Holmberg | www.dextechmedical.com |
Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. Its principal product candidate is OsteoDex that has completed phase IIb clinical trial for the treatment of skeletal metastases in castration resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, to treat acromegaly, neuroendocrine tumors, and palliative treatment for advanced prostate cancer; and PSMA-binding conjugates for the target-specific treatment of mCRPC that overexpresses prostate specific membrane antigen (PSMA).
Dextech Medical AB Fundamentals Summary
| LQ0 fundamental statistics | |
|---|---|
| Market cap | €6.89m |
| Earnings (TTM) | -€388.82k |
| Revenue (TTM) | €466.74k |
14.8x
P/S Ratio-17.7x
P/E RatioIs LQ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LQ0 income statement (TTM) | |
|---|---|
| Revenue | kr5.43m |
| Cost of Revenue | kr23.00k |
| Gross Profit | kr5.41m |
| Other Expenses | kr9.94m |
| Earnings | -kr4.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 99.58% |
| Net Profit Margin | -83.30% |
| Debt/Equity Ratio | 0% |
How did LQ0 perform over the long term?
See historical performance and comparison